<img height="1" width="1" style="display:none" src="https://q.quora.com/_/ad/fddcdc9dc8954bf7bdefaa9d33414665/pixel?tag=ViewContent&amp;noscript=1">

How are intranasal medicines making a dent in the fight against respiratory illnesses like COVID-19?

April 13, 2021

Leyden Labs, a Dutch biotechnology company focusing on respiratory viruses, recently received €40 million (about US$47 million) in a Series A round led by GV. Leyden Labs is developing intranasal medicines to prevent infection from a number of respiratory pathogens, including COVID-19. 

What did ResoluteAI learn about intranasal medicines and respiratory illnesses?


News on respiratory illnesses and intranasal medicines in 2020 focused on a number of areas, including bat- and bird-borne diseases.

Below are some recent articles on intranasal medicines and respiratory illnesses:

News in 2020 on intranasal sprays and respiratory illnesses covered a number of areas.News in 2020 on intranasal sprays and respiratory illnesses

Clinical trials in progress on intranasal medicines and respiratory illnesses include:


Individuals who have received the most grants on the topic are:


To learn more about how Foundation can help you make connections, schedule a demo or click "Let's talk" below to connect.

Let's talk


Lesley Pink

Lesley Pink, our senior digital editor/writer, has written across a range of industries including artificial intelligence, actuarial science, government, law, and financial journalism. She's a fan of the serial comma and mint chocolate chip ice cream. And no, pink is not her favorite color. You can reach Lesley at lesley@resolute.ai.